Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

AMPLATZER Cardiac Plug Clinical Trial

2 april 2020 uppdaterad av: Abbott Medical Devices

Amplatzer Cardiac Plug Clinical Trial

The objective of this study is to evaluate the safety and effectiveness of the ACP in subjects with nonvalvular atrial fibrillation by demonstrating that the device is non-inferior to optimal medical therapy (OMT) with respect to the primary effectiveness endpoint and superior to OMT with respect to primary safety endpoint.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

97

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Förenta staterna, 90017
        • Good Samaritan Hospital
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
        • University of Colorado Denver
      • Littleton, Colorado, Förenta staterna, 80120
        • South Denver Cardiology Associates
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30308
        • Emory Midtown Hospital and Emory University Hospital
      • Atlanta, Georgia, Förenta staterna
        • St. Joseph's Hospital and Research Institute
    • Iowa
      • Iowa City, Iowa, Förenta staterna, 52242
        • University of Iowa Hospitals & Clinics
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40506
        • University of Kentucky
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48202
        • Henry Ford Hospital
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Spectrum Health
      • Southfield, Michigan, Förenta staterna, 48075
        • Providence Hospital
    • Minnesota
      • Saint Cloud, Minnesota, Förenta staterna, 56303
        • St. Cloud Hospital/CentraCare Heart and Vascular Clinic
      • Saint Paul, Minnesota, Förenta staterna, 55102
        • HealthEast St. Joseph's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • University of Pennsylvania
      • York, Pennsylvania, Förenta staterna, 17405
        • York Hospital
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29401
        • Roper Hospital/PMG Research of Charleston
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Memorial Hermann Hospital
    • Wisconsin
      • Wausau, Wisconsin, Förenta staterna, 54401
        • Aspirus Heart & Vascular Institute

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation
  • Subject must be ≥18 years of age
  • Subject must be on warfarin or dabigatran therapy
  • Subject must be eligible for long term warfarin or dabigatran therapy
  • Subject must have a CHADS(2) score of 2 or greater

Summary of Exclusion Criteria:

  • Subject who requires warfarin or dabigatran for a condition other than AF
  • Subject who is on clopidogrel or another P2Y12 platelet inhibitor such as prasugrel or ticagrelor
  • Subject who has an absolute or relative contraindication to aspirin, or warfarin and dabigatran
  • Subject with a New York Heart Association (NYHA) classification equal to IV
  • Subject with an implanted or surgical repair atrial septal defect (ASD) device or patent foramen ovale (PFO) device
  • Subject with aortic or mitral valve regurgitation of grade 2+ or greater
  • Subject with left ventricular ejection fraction (LVEF) ≤30
  • Subject with mitral or aortic prosthetic valve
  • Subject with a history of hemorrhagic or aneurysmal stroke
  • Subject with a history of previous radio frequency (RF) ablation for atrial fibrillation
  • Subject with a body mass index (BMI) ≥40
  • Subject with a history of acute or recent MI, or unstable angina, or coronary artery bypass graft surgery (within 6 months)
  • Subject who is on aspirin dose therapy greater than 81mg/day at time of enrollment

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Device
AMPLATZER Cardiac Plug
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
Aktiv komparator: Optimal Medical Therapy (control)
Warfarin Dabigatran
AMPLATZER Cardiac Plug is a percutaneous transcatheter device

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Acute Safety - Procedure Related SAEs From Randomization Through Discharge For Device Arm Only
Tidsram: From Randomization to Discharge Visit

An analysis comparing the rate of procedure related serious adverse events that occur in the device arm to a performance goal determined from literature reported rates for similar procedural techniques.

The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT).

However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm below. The secondary endpoint analysis requirement was removed from the protocol.

From Randomization to Discharge Visit
Long-term Safety - Device Arm Only
Tidsram: Randomization to 2 year follow-up

All-Cause Mortality and Major Bleeds Through 2 years in device arm subjects only. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT).

However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol.

Randomization to 2 year follow-up
Effectiveness Endpoint - Device Arm Only
Tidsram: Randomization through 2 year follow up

Occurrence of ischemic stroke and peripheral thromboembolism in the device arm. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT).

However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol.

Randomization through 2 year follow up

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 april 2010

Primärt slutförande (Faktisk)

6 december 2018

Avslutad studie (Faktisk)

6 december 2018

Studieregistreringsdatum

Först inskickad

5 maj 2010

Först inskickad som uppfyllde QC-kriterierna

5 maj 2010

Första postat (Uppskatta)

6 maj 2010

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 april 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 april 2020

Senast verifierad

1 april 2020

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera